Navigation Links
Aeras and CNBG sign agreement on tuberculosis vaccine R&D
Date:1/9/2012

ROCKVILLE, MD, USA/BEIJING, CHINA -- The global fight against the tuberculosis epidemic receives a boost today as Aeras and the China National Biotec Group (CNBG) announce that they have reached final agreement to jointly develop new tuberculosis (TB) vaccines. The agreement between the leading non-profit developer of TB vaccine candidates and the largest biotechnology corporation in China signals a commitment by both to engage and strengthen the role of China in the fight against one of the world's deadliest infectious disease killers.

Xiaoming Yang, President of CNBG, said of the agreement: "CNBG has a great deal of expertise and energy to invest in this partnership. Not only is TB a public health crisis of the developing world, it is also a priority health issue here in China. We look forward to working with our counterparts at Aeras to develop new TB vaccines that will help stop tuberculosis in all corners of the world."

Multiple research institutes operating under the umbrella of CNBG will engage with Aeras on a strategy focused on the joint development, manufacturing and distribution of affordable new TB vaccines for use globally. The agreement spans all aspects of TB vaccine development from vaccine discovery to pre-clinical research to clinical research to manufacturing and positions CNBG as a major emerging player in the TB vaccine field.

Bacille Calmette-Gurin (BCG), the only currently-licensed TB vaccine, does not prevent pulmonary TB, the most common form of the disease. As part of this collaboration, Aeras will license its recombinant BCG (rBCG) platform which aims to improve upon the current TB vaccine and other technologies to CNBG. The groups will jointly develop novel TB vaccines using the rBCG platform and other technologies provided by Aeras or CNBG's research institutes. A variety of candidate booster vaccines will be engineered to match the new constructs with a goal to create more efficacious and longer-lasting protection against TB disease.

A keystone of this broad collaboration is the implementation of joint product development teams to develop and execute comprehensive plans for both the research and clinical development of TB vaccines and the design, construction and validation of a vaccine process development and manufacturing facility in China, which will receive financial support and technical expertise provided by Aeras.

"The synergy created by bringing together our scientific and manufacturing expertise could have a substantial impact on efforts to advance innovative candidates in TB vaccine development," said Jim Connolly, President and CEO of Aeras. "We look forward to working with the largest biotech corporation in a country with the skills, resources and TB disease burden to play a major role in overcoming the complex challenges of TB vaccine R&D."

TB is a major public health priority in China, where there are more than one million new TB cases every year. Globally, the TB epidemic is responsible for the deaths of 1.4 million people annually.


'/>"/>
Contact: Jamie Rosen
jrosen@aeras.org
301-547-2853
Aeras
Source:Eurekalert

Related biology news :

1. Aeras awarded €11.7 million ($16 million) grant from Dutch government
2. Aeras-led research consortium receives FDA support
3. ResearchMoz: Bioinformatics Partnering Terms and Agreements
4. Spectros Corporation Signs Distribution Agreements in Middle East
5. SomaLogic and Ambergen announce agreement for commercial applications of photocleavable biotin
6. Missouri Botanical Garden signs exchange agreement with 3 botanical institutions in China
7. BGI announces collaborative research agreements with Oregon State University
8. Veritec and National Identity Solutions (NIS) Sign Significant License Agreement Entering Into a $500 Billion Marketplace
9. QB3 signs agreement to accelerate innovation
10. Wayne State announces license agreement for breakthrough approaches to vision restoration
11. SomaLogic announces agreement with leading global pharma company to accelerate R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):
(Date:5/24/2016)... ... May 24, 2016 , ... Cell therapies for a ... accelerated by research at Worcester Polytechnic Institute (WPI) that yielded a newly patented ... regeneration. , The novel method, developed by WPI faculty members Raymond Page, PhD, ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Last week, ... for corporate executives and entrepreneurs, held The Future of San Diego Life Science event ... San Diego life science community attended the event with speakers Dr. Rich Heyman, former ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... Board of Directors has approved the payment of a quarterly ... The cash dividend of $0.24 per share ... stockholders of record as of the close of business on ... approval of the Board of Directors and may be adjusted ...
Breaking Biology Technology: